As we reach the end of July, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI. To subscribe to BPIQ companies Learn more here. Table 1. BPIQ company weekly moves and YTD moves See the biggest moves from last week below: *We never send you spam - unsubscribe anytime Highlights for the week Biggest positive move Biggest negative move SIGA41.37%4.87$1,244,670,180https://www.bpiq.com/companies/SIGAWHO’s declaration of a monkeypox global health emergency points to an increasing need for treatment, which is why SIGA is about to print large amounts of cash.sourceAKTX20.88%0.79$65,620,776https://www.bpiq.com/companies/AKTXAkari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophysource SIGA41.37%128.59%4.24WHO’s declaration of a monkeypox global health emergency points to an increasing need for treatment, which is why SIGA is about to print large amounts of cash.TNXP41.18%-85.33%4.62Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox InfectionENDP32.50%-85.90%0.27Buxton Helmsley Issues Letter to Endo International Plc. Directors, Relating to Financial DisclosuresOMER26.72%-22.55%0.63FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal HemoglobinuriaATNX-20.31%-62.50%0.14Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical OncologyAUPH-21.12%-64.23%0.62Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent ReviewLXRX-22.73%-39.59%0.94Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private PlacementSAVA-28.78%-62.63%1.58Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug More